title: Thinning bone and inhaled corticosteroid in COPD: what to do until there is definitive proof?
authors.affiliation: Department of Medicine, Respiratory Division, University of British Columbia, and the Heart and Lung Institute, St. Paul's Hospital, Vancouver, BC, Canada. Electronic address: pman@providencehealth.bc.ca.
authors.forename: S F Paul
authors.initials: SFP
authors.lastname: Man
authors.affiliation: Department of Medicine, Respiratory Division, University of British Columbia, and the Heart and Lung Institute, St. Paul's Hospital, Vancouver, BC, Canada.
authors.forename: Don D
authors.initials: DD
authors.lastname: Sin
mesh_terms: D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D004164:Diphosphonates / Q000494:pharmacology; D005260:Female; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced* / Q000453:epidemiology; D015995:Prevalence; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D012307:Risk Factors
chemical_list: D000305:Adrenal Cortex Hormones; D004164:Diphosphonates